-- Study will evaluate the safety and preliminary efficacy of AR-13503 SR Implant as monotherapy and in combination with aflibercept -- DURHAM, N.C. --(BUSINESS WIRE)--Aug. 20, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery,
Conference Call and Webcast Today, August 7 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Aug. 7, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 25, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 9, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases
